{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:28:56Z","timestamp":1791851336363,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jdiacomp.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T12:30:24Z","timestamp":1486729824000},"page":"1215-1221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure"],"prefix":"10.1016","volume":"31","author":[{"given":"Mikhail","family":"Kosiborod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gause-Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sonesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0005","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/dc10-1123","article-title":"Diabetes and heart failure in patients with coronary disease: separating markers from mediators","volume":"33","author":"McGuire","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0010","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.108.821843","article-title":"Elevated admission glucose and mortality in elderly patients hospitalized with heart failure","volume":"119","author":"Kosiborod","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.106.661405","article-title":"Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk","volume":"115","author":"Held","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0025","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc10-0286","article-title":"Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study","volume":"33","author":"van Melle","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0030","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0045","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","article-title":"Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry","volume":"77","author":"Shindler","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0050","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0055","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0060","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0075","first-page":"A266","article-title":"Dapagliflozin lowered ambulatory blood pressure in patients with T2DM and hypertension inadequately controlled by a renin\u2013angiotensin system blocker with or without another agent","volume":"63","author":"Weber","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0080","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0095","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0105","first-page":"A11105","article-title":"Cardiovascular safety of the SGLT2 inhibitor dapagliflozin: meta-analysis with >6000 patient-years exposure","volume":"128","author":"Langkilde","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2017.02.001_bb0120","first-page":"1072","article-title":"Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk","volume":"35","author":"Sonesson","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cardfail.2009.12.021","article-title":"The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists","volume":"16","author":"Ghali","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0135","article-title":"Safety and efficacy of dapagliflozin in patients with T2DM and cardiovascular disease receiving loop diuretics","volume":"64","author":"Cefalu","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0140","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0155","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0160","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0165","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0180","first-page":"2268","article-title":"A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT)","volume":"132","author":"Margulies","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0185","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0190","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0195","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.107.690768","article-title":"Patterns of weight change preceding hospitalization for heart failure","volume":"116","author":"Chaudhry","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0200","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.2337\/dc11-s220","article-title":"Hypoglycemia and cardiovascular risks","volume":"34","author":"Frier","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0210","author":"AstraZeneca"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0215","author":"Saint Luke's Health System"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0220","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-016-0381-x","article-title":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial","volume":"15","author":"Tanaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0225","author":"AstraZeneca"},{"key":"10.1016\/j.jdiacomp.2017.02.001_bb0230","author":"Boehringer Ingelheim"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716308613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716308613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:25:26Z","timestamp":1536045926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716308613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1056872716308613"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.02.001","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}